FierceBiotechOriginal article
{"a":[{"_":"Immunovant ends cutaneous lupus program after phase 2 flop","$":{"href":"/biotech/immunovant-ends-cutaneous-lupus-program-after-phase-2-flop","hreflang":"en"}}]}
Phase 2negativeIMVT-1402Negative
AI Analysis
Summary
Immunovant discontinues IMVT-1402 development in cutaneous lupus erythematosus following a failed Phase 2 trial, eliminating one development pathway for the anti-FcRn antibody candidate.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Failed midphase test; program discontinued
Importance:6/10
Sentiment:
-0.85
Phase 2 failureProgram terminationAnti-FcRn antibodyCutaneous lupus
Related Companies
Read the original article
Published by FierceBiotech on September 23, 2026 9:00 AM